<DOC>
	<DOCNO>NCT00232310</DOCNO>
	<brief_summary>Double blind study assess versus placebo efficacy SSR149744C conversion atrial fibrillation/flutter sinus rhythm time planned electrical cardioversion .</brief_summary>
	<brief_title>Double Blind Placebo COntrolled Dose Ranging studY eFficacy safEty SSR149744c 300 600 mg Conversion Atrial Fibrillation / fluttEr</brief_title>
	<detailed_description>This dose range multicenter , multinational , randomize , double blind , placebo control , parallel arm study . Patients AF/AFL randomize one two dos SSR149744C . The efficacy SSR149744C base proportion patient convert normal sinus rhythm end treatment period ( 48 hour post first dose ) . Patients receive study drug D1 D2 . Patients convert pharmacologically sinus rhythm undergo electrical cardioversion D3 .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Atrial Flutter</mesh_term>
	<criteria>AF/AFL &gt; 72 hour document 2 12lead ECGs separate least 72 hour indication electrical cardioversion current AF/AFL episode judge investigator . MAIN CRITERIA ( nonexhaustive list ) : Women childbearing potential without adequate birthcontrol , Pregnant Women , Breastfeeding woman , condition increase risk severe antiarrhythmic drug side effect , permanent pacemaker , permanent AF/AFL , contraindication anticoagulant , severe leave ventricular dysfunction , severe associate condition .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Atrial Flutter</keyword>
	<keyword>Electric Countershock</keyword>
</DOC>